bullish
Pharmaron (康龙化成) Post-IPO: A/H Convergence Post Connect Inclusion Supports A Trade
471 Views02 Jan 2020 17:52
Pharmaron, the second-largest contract research organization (CRO) in China, was listed in Hong Kong on November 28th. The deal was anchored by a...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- Pharmaron Placement - Strong Track Record08 Jun 2021
- Pharmaron Buy Support21 Sep 2020
- Long Pharmaron/Short Wuxi: Take Profit Now, A-Share Pullback the Key Risk23 Jan 2020
- Pharmaron (康龙化成) Post-IPO: A/H Convergence Post Connect Inclusion Supports A Trade02 Jan 2020
- Pharmaron (康龙化成) A+H: Allocation and Thoughts on Trading27 Nov 2019
- Pharmaron (康龙化成) A+H: Decent H/A Discount and Cornerstone Line-Up12 Nov 2019
x